| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/07/2006 | CN1784220A Use of effectors of glutaminyl and glutamate cyclases |
| 06/07/2006 | CN1782086A Adeno-associated virus mediating trigenic cell expression system |
| 06/07/2006 | CN1781943A South China sea conus littertus linnaeus nervotoxin and its coding sequence and use |
| 06/07/2006 | CN1781920A Polycyclic guanine phosphodiesterase v inhibitor |
| 06/07/2006 | CN1781910A Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
| 06/07/2006 | CN1781890A 糖皮质激素受体调制剂 Glucocorticoid receptor modulators |
| 06/07/2006 | CN1781549A Adeno-associated virus vector preparation and medicinal composition containing it and its use |
| 06/07/2006 | CN1781545A Method for extracting herbal medicine |
| 06/07/2006 | CN1781534A Chinese medicine for treating mad diseases |
| 06/07/2006 | CN1781527A Xingnaoling magic plaster |
| 06/07/2006 | CN1781523A Schisandra chinensis soft capsule |
| 06/07/2006 | CN1781520A Method for preparing Qingkailing preparation |
| 06/07/2006 | CN1781516A Method for preparing piper laetispicum extract, extract and its use |
| 06/07/2006 | CN1781509A Composition of luffa seed oil |
| 06/07/2006 | CN1781506A American ginseng and royal jelly soft capsule |
| 06/07/2006 | CN1781481A Easy disintegrating solid preparation of modafinil |
| 06/07/2006 | CN1781480A Treatment of attention deficit/hyperactivity disorder |
| 06/07/2006 | CN1258551C Preparing method of degradable polymer |
| 06/07/2006 | CN1258536C Pineapple acid glycoside compound and its use |
| 06/07/2006 | CN1258530C Crystalline base of citalopram |
| 06/07/2006 | CN1258379C Botulinum toxin pharmaceutical composition |
| 06/07/2006 | CN1258372C Chinese medicinal composition for treating intestine irritable syndrome and its preparing method |
| 06/07/2006 | CN1258363C Nimodipine adhesive sheet |
| 06/07/2006 | CN1258359C Pharmaceutical compositions |
| 06/06/2006 | US7057078 for treatment of depression and Alzheimer's disease |
| 06/06/2006 | US7057076 which have improved receptor binding affinity via substituted alkyl side chains at the c-3 position; may contain terpene funtionality combined with resorcinol moieties; for treatment of nervous system disorders and cardiovascular disorders |
| 06/06/2006 | US7057051 Substituted imidazoles as cannabinoid receptor modulators |
| 06/06/2006 | US7057047 reacting 2-diaminopyridine with malic/sulfuric acid to form 2-amino-7-hydroxy-1,8-naphthyridine sulfuric acid salt, reacting in solvent to form phthalimidyl naphthyridine, chlorinating, reducing to hydroxyindolinone, then reacting with 5-methyl-2-oxo-hexyltriphenylphosphonium halide to form racemate |
| 06/06/2006 | US7057039 Method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I |
| 06/06/2006 | US7056944 Pyrazole compositions useful as inhibitors of erk |
| 06/06/2006 | US7056939 4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3) |
| 06/06/2006 | US7056938 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 06/06/2006 | US7056937 Sulfonylquinoxalone derivatives as bradykinin antagonists |
| 06/06/2006 | US7056933 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc. |
| 06/06/2006 | US7056930 for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders |
| 06/06/2006 | US7056922 Acylamino cyclopropane derivatives |
| 06/06/2006 | US7056921 Substituted chroman derivatives |
| 06/06/2006 | US7056920 useful for treating disorders or conditions that are associated with CRF or CRF1 receptors, such as anxiety disorders, depression, and stress related disorders |
| 06/06/2006 | US7056915 Compounds useful as reversible inhibitors of cysteine proteases |
| 06/06/2006 | US7056914 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 06/06/2006 | US7056904 Therapy for bone disorders; osteoporosis; vitamin deficiency |
| 06/06/2006 | US7056903 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists |
| 06/06/2006 | US7056902 4-dedimethylamino tetracycline compounds |
| 06/06/2006 | US7056895 1-(3,4-dihydroxy-5-methylol-tetrahydrofur-2-yl),3-amidino-1H-1,2,4- triazoles; infections, infestations, autoimmune diseases; anticarcinogenic and -tumor agents; HIV, hepatitis C, human papilloma virus and giant cell arteritis |
| 06/06/2006 | US7056528 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 06/06/2006 | US7056527 Patches containing buprenorphine hydrochloride |
| 06/06/2006 | US7056525 Use thereof in human and animal foods, cosmetics and pharmaceuticals; soft gelatin capsules |
| 06/06/2006 | US7056500 Polymer conjugates of opioid antagonists |
| 06/06/2006 | US7056275 Radiotherapy |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2316902C Alpha-aminoamide derivatives useful as analgesic agents |
| 06/06/2006 | CA2282585C Pyrazine compounds |
| 06/06/2006 | CA2277951C Imino-aza-anthracyclinone derivatives |
| 06/06/2006 | CA2258895C Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders |
| 06/06/2006 | CA2199468C 1,2,3,4-tetrahydroquinoxalinedione derivative |
| 06/06/2006 | CA2160366C Risperidone pamoate |
| 06/06/2006 | CA2154572C Use of riluzole for the treatment of neuro-sida |
| 06/01/2006 | WO2006058303A2 Modulators of muscarinic receptors |
| 06/01/2006 | WO2006058120A1 Bicyclic inhibitors or rho kinase |
| 06/01/2006 | WO2006058059A2 Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject |
| 06/01/2006 | WO2006058008A1 Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| 06/01/2006 | WO2006057870A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057869A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057860A1 Potentiators of glutamate receptors |
| 06/01/2006 | WO2006057546A1 Use of dexrazoxane in the treatment of acute cerebral ischemia |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006057211A1 Therapeutic agent for drug dependence |
| 06/01/2006 | WO2006056874A1 Salt form |
| 06/01/2006 | WO2006056783A2 Structured phospholipids for treating autoimmune and neurodegenerative diseases |
| 06/01/2006 | WO2006056600A1 Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic a ivity |
| 06/01/2006 | WO2006056129A1 Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof |
| 06/01/2006 | WO2006056097A1 A pharmaceutical composition for treating senile dementia |
| 06/01/2006 | WO2006041830A3 Cgrp receptor antagonists |
| 06/01/2006 | WO2006038070A3 Compositions and methods for modulating gated ion channels |
| 06/01/2006 | WO2006036015A3 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| 06/01/2006 | WO2006032146A8 The use of a modafinil compound for the treatment of problem gambling |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2006030300A3 Processes for the preparation of olanzapine |
| 06/01/2006 | WO2006028957A8 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 06/01/2006 | WO2006027692A3 Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 06/01/2006 | WO2006012603A3 Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| 06/01/2006 | WO2006010050A3 Modulation of synaptogenesis |
| 06/01/2006 | WO2005107752A3 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 06/01/2006 | WO2004066932A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 06/01/2006 | WO2004004656A3 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060117414 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 06/01/2006 | US20060116520 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| 06/01/2006 | US20060116518 Novel phenanthridines |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116413 Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heteroyclic amide bond isostere |
| 06/01/2006 | US20060116395 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116385 Novel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116379 Compounds exhibiting type X sPLA2 inhibiting effect |
| 06/01/2006 | US20060116378 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity |
| 06/01/2006 | US20060116364 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer |
| 06/01/2006 | US20060116362 Nobel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116341 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity |
| 06/01/2006 | US20060116339 Antisense modulation of purinoreceptor p2x3 |